Biosimilars and JAK Inhibitors Continue to Gain Popularity in the EU Rheumatoid Arthritis Market, According to Spherix Global Insights
Biosimilar use in the EU5 rheumatoid arthritis market leads to erosion of name brand drugs; JAK inhibitors slowly penetrate the market, while perceived safety risks may limit prescribing EXTON, Pa., Aug. 30, 2019 /PRNewswire/ — Twice a year, Spherix collects the responses of ~250 EU5 rheumatologists as part of their RealTime Dynamix™: Rheumatoid Arthritis (EU) […]
Launch of AbbVie’s Upadacitinib Expected to Cause a Stir in the US Rheumatoid Arthritis Market, According to Spherix Global Insights
As the user base of Regeneron’s Kevzara and Eli Lilly’s Olumiant continue to expand, US rheumatologists gear up for AbbVie’s JAK inhibitor to enter the market – with Pfizer’s Xeljanz most at risk for displacement Download Report Overview EXTON, Pa., July 18, 2019 /PRNewswire/ — The latest report included in Spherix’s RealTime Dynamix™ Rheumatoid Arthritis (US) […]
US Rheumatologists Show Continued Uptake of Eli Lilly’s Olumiant for the Treatment of Rheumatoid Arthritis, Though Safety Concerns and Lack of Experience in the Market Withhold Full Potential
According to a recent report by Spherix Global Insights, Eli Lilly’s Olumiant and Regeneron’s Kevzara enjoy continued uptake, though rising safety concerns associated with the JAK inhibitor class may blunt Olumiant’s trajectory Download Report Overview EXTON, Pa., March. 25, 2019 /PRNewswire/ — Overall brand share among biologic/JAK-treated patients in the US rheumatoid arthritis (RA) market has […]
Recent Data Collected by Spherix Global Insights Highlights Key US vs. EU Differences Between Perceptions and Adoption of Eli Lilly’s Olumiant and Pfizer’s Xeljanz for the Treatment of Rheumatoid Arthritis
Despite the introduction of Olumiant to the US market in June of 2018, Xeljanz has been able to maintain preference among stateside rheumatologists; however, in the EU, where Olumiant secured the first-to-market position, the story is quite different. EXTON, Pa., January 16, 2019 /PRNewswire/ — Analysis of Spherix Global Insights’ RealTime Dynamix™: Rheumatoid Arthritis market tracker […]
In Rheumatoid Arthritis, TNF Cycling Continues to Be Highly Prevalent, Though Alternate Mechanism Agents Are Capturing a Greater Percentage of the Switching Population Compared to the Prior Year
According to the latest patient audit analysis from Spherix Global Insights, biosimilars have gained ground, but the overall infliximab pie in the rheumatoid arthritis switching segment is beginning to shrink Download Report Overview Exton, PA., December 4, 2018 /PRNewswire/ — In Spherix Global Insight’s third annual RealWorld Dynamix: Biologic/JAK Switching in Rheumatoid Arthritis (US) study, […]
More Rheumatologists are Using Pfizer’s Xeljanz in Psoriatic Arthritis Patients, Outpacing the Impressive Growth Displayed by Eli Lilly’s Taltz in the Previous Quarter
Download Report Overview EXTON, Pa., Oct. 8, 2018 /PRNewswire/ — The most recent quarterly results of a study conducted by Spherix Global Insights with 100 US rheumatologists reveals that Xeljanz’s user base has increased by a greater margin than the user base for Taltz for the treatment of psoriatic arthritis (PsA) over the last three […]
Ankylosing Spondylitis Market Largely Dominated by TNF-Inhibitors, Though Novartis’ Cosentyx Enjoyed Significant Year Over Year Gains and a Growing Percent of Rheumatologists Report Off-Label Use of Pfizer’s Xeljanz
With no current FDA approved biologics for the treatment of non-radiographic axial spondyloarthropathy, overall penetration of biologics/JAKs is significantly lower than for ankylosing spondylitis; however, when these agents are prescribed, brand usage closely mirrors the ankylosing spondylitis indication, according to a new publication by Spherix Global Insights Download Report Overview EXTON, Pa., September 6, 2018 […]
US Rheumatologists’ Early Views on Eli Lilly’s Olumiant for the Treatment of Rheumatoid Arthritis Show Uphill Battle, While Pfizer’s Xeljanz Holds Ground as the Preferred JAK Inhibitor
The introduction of Olumiant after lengthy delays means Sanofi/Regeneron’s Kevzara is no longer the “new kid on the block” and has recently boasted significant growth. Download Report Overview EXTON, Pa., Aug. 20, 2018 /PRNewswire/ — Spherix Global Insights’ third quarter update of RealTime Dynamix™: Rheumatoid Arthritis (US) captured initial insights on Eli Lilly’s long-awaited launch […]
Lupus Clinical Trials May Not Be Representative of Real-World Population, Report Suggests
From: Lupus News Today By: Iqra Mumal Patients participating in Phase 3 clinical trials testing new therapies for systemic lupus erythematosus (SLE) are not necessarily representative of real-world patient populations, according to a new report. Even if the therapies being investigated reach the market, real-world experiences may differ significantly from trial results […]
Analysis of Over 1,000 Systemic Lupus Erythematosus Patients Reveals Real World Patient Populations are Not Representative of Clinical Trial Samples
While the systemic lupus erythematosus (SLE) pipeline has progressed with agents such as Janssen’s Stelara, AstraZeneca/MedImmune’s anifrolumab, Neovacs’ INF-K, and ImmuPharma’s Lupuzor, historically, most agents in development do not make it past phase III trials, resulting in an exceptionally high unmet need. Download Report Overview EXTON, Pa., July 25, 2018 /PRNewswire/ — To better understand […]
